Antineuronal antibodies in patients with neuroblastoma: Relationships with clinical features

Andrea Salmaggi, Roberto Luksch, Maria Grazia Forno, Annalisa Pozzi, Antonio Silvani, Amerigo Boiardi, Marco Gasparini, Raffaello Nemni

Research output: Contribution to journalArticlepeer-review


We evaluated the frequency of serum antineuronal antibodies in a cohort of 39 neuroblastoma patients and related their presence to clinical features. Twelve patients displayed antineuronal antibodies at immunocytochemistry. Only one of these 12 patients suffered from a clinically overt paraneoplastic syndrome. No significant differences emerged between autoantibody-positive and autoantibody-negative patients in terms of progression-free and overall survival, although when only patients evolving to disease progression were considered, the time interval between diagnosis and progression was slightly longer in autoantibody-positive patients.

Original languageEnglish
Pages (from-to)953-957
Number of pages5
Issue number6
Publication statusPublished - Nov 1997


  • Antineuronal antibodies
  • Clinical outcome
  • Neuroblastoma
  • Paraneoplastic syndromes

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Antineuronal antibodies in patients with neuroblastoma: Relationships with clinical features'. Together they form a unique fingerprint.

Cite this